ClinicalTrials.gg
RecruitingNCT06703177Updated Dec 3, 2025

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

A Phase 1/2 interventional study of SHR-1826 and SHR-4642 in Advanced Solid Tumors, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
876
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation and written ;
  2. 18-75 years older, no gender limitation;
  3. (ECOG) score: 0-1;
  4. With a ≥ 3 months;
  5. diagnosed advanced solid tumor;
  6. Be able to provide fresh or archived tumour tissue;
  7. At least one according to v1.1;
  8. Adequate bone marrow reserve and organ function;
  9. is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Meningeal history or clinical symptoms of central nervous system metastasis;
  2. Previous or co-existing ;
  3. Spinal cord compression that was not treated radically by surgery and/or radiotherapy was excluded;
  4. Uncontrollable tumor-related pain;
  5. Previously received antiboy-coupled drug therapy with topoisomerase I inhibitor toxin; Previously received EGFR/c-Met double antibody;
  6. Received systemic antitumor therapy before the first dose;
  7. Have undergone major surgery other than diagnosis or within 28 days prior to initial dosing; Minor traumatic surgery within 7 days prior to first dosing;
  8. For the first time, a study was conducted to treat patients with radiation therapy exceeding the prescribed dose before study treatment;
  9. Received Other drugs treatments 4 weeks prior to the initiation of the study treatment;
  10. Unresolved 5.0>grade 2 toxicities from previous anticancer therapy;
  11. A history of interstitial pneumonia/non-infectious pneumonia;
  12. Accompanied by uncontrolled pleural effusion and pericardial effusion; Moderate or severe ascites with clinical symptoms;
  13. Study the presence of intestinal obstruction or the presence of signs or symptoms of intestinal obstruction 6 months before first dosing;
  14. With poorly controlled or severe cardiovascular disease;
  15. Active , ;
  16. Patients with a history of immunodeficiency;
  17. Severe infection 30 days before the first dose.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
876 participants (estimated)

Study arms

  • Experimental
    Single group

    Drug: SHR-1826 · Drug: SHR-4642 · Drug: SHR-9839 · Drug: SHR-8068 · Drug: Bevacizumab Injection · Drug: Fluorouracil Injection · Drug: Calcium Folinate Injection · Drug: Adebrelimab Injection · Drug: Capecitabine tablets

Interventions

06

What researchers measure

Primary outcomes

  1. RP2D (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  2. AE (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  3. Objective response rate (ORR) (Phase 2)

    Time frame: Screening up to study completion, an average of 1 year.

Secondary outcomes

  1. Objective response rate (ORR) (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  2. Disease control rate (DCR) (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  3. Duration of response (DoR) (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  4. Progression-free survival (PFS) (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  5. Overall survival (OS) (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  6. Drug Resistant Antibody (ADA) (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  7. Blood concentration of SHR-1826 (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  8. Blood concentration of free toxin SHR169265 (Phase 1)

    Time frame: Screening up to study completion, an average of 1 year.

  9. Disease control rate (DCR) (Phase 2)

    Time frame: Screening up to study completion, an average of 1 year.

  10. Duration of response (DoR) (Phase 2)

    Time frame: Screening up to study completion, an average of 1 year.

  11. Progression-free survival (PFS) (Phase 2)

    Time frame: Screening up to study completion, an average of 1 year.

  12. Overall survival (OS) (Phase 2)

    Time frame: Screening up to study completion, an average of 1 year.

  13. AE (Phase 2)

    Time frame: Screening up to study completion, an average of 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jan 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 25, 2024
StartActual
Feb 18, 2025
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jul 1, 2027
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703177
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Feb 18, 2025
Primary completion
Jan 1, 2026 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Dec 3, 2025

Study contacts

Rongfu Mao, MD
Contact
rongfu.mao@hengrui.com
+86-021-61053363
Hao Shen, BS
Contact
hao.shen@hengrui.com
+86-021-61053363

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1826

Start the discussion